An extension study to evaluate the long-term efficacy and safety of minzasolmin (UCB0599) in study participants with Parkinsons disease
Brief description of study
Subjects currently enrolled in the PD0053 can be enrolled in this study. Subjects will take UCB0599 capsules twice a day at either 180 mg or 360 mg approximately 12 hours apart. The start of the study will overlap with the end of the parent study and run for 30 months with a one month safety follow up at the conclusion of treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
